DRMA Company Profile and Key Details

DRMA has shown mixed momentum, gaining 19.23% over the past week and -45.34% over the past quarter, though year-to-date performance is down -6.47%. Short-term trend indicators are bullishly aligned (SMA20 -23.45%, SMA50 -37.35%, SMA200 -72.73%). The stock’s 14-day RSI is 40.35 (neutral), while the ATR of 0.31 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -94.73% below its high and over 8.19% above its low. Average 10-day trading volume of 3.03 million shares is significantly above the 3-month average of 402.97 thousand, indicating heightened recent market interest.

Dermata Therapeutics, Inc. has 4.02 million shares outstanding. The public float is 3.17 million shares, elevated short interest at 2.06% of float. This equals 64.86 thousand shares. The short ratio is 0.68 days. Institutional investors hold 9.81% of the float. Insiders own 24.82%. PROEHL GERALD T holds 59.51 thousand shares, HALE DAVID F has 35.71 thousand shares and Bedoya-Toro Munera Maria E has 1.01 thousand shares. Over the past six months, insider transactions show balanced activity. They sold 11.00 shares across 1 transactions.

Dermata Therapeutics, Inc. generated EPS of -$20.29 over the past year. Five-year average earnings growth is 43.22%. The latest quarter delivered EPS of -$0.74. The next quarter is forecast at -$1.54. Next year's EPS is expected at $44.31. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $10.00 to $10.00. The high target offers 825.93% upside. The low target suggests 825.93% downside. The mean target is $10.00. This offers 825.93% upside. Dermata Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended August 11, 2026, missed forecasts by 34.55%. The prior quarter beat by -9.43%. Over the last six quarters, Apple has recorded several small beats. These include 900.0% in May 14, 2025.

Dermata Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $20.66. This means the shares are trading below this model’s fair value.

Dermata Therapeutics, Inc. (NASDAQ:DRMA) closed at $1.08 USD, losing -$0.04 (-3.57%) from the previous close of $1.12. The stock is currently mid-range between its 52-week high and low $0.95 and $6.58. With a market capitalization of about $736.08 thousand, Dermata Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.66). Key stats such as the average daily volume over the past year has been around 385.57 thousand shares, in line with its 52-week average. Headquartered in San Diego, CA, Dermata Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Gerald T. Proehl, the company employs approximately 9 people and listed since August 13, 2021. Dermata Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise, concentrating its efforts on discovering, advancing, and bringing to market novel pharmaceutical treatments designed to address various medical and cosmetic skin ailments.

Dermata Therapeutics, Inc. trades at a P/E ratio of -0.21, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.66 suggesting the stock is closer to book value. The P/FCF stands at -0.09, also above market averages.

Dermata Therapeutics, Inc. (NASDAQ:DRMA) shares are flat -6.47% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Dermata Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.21. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $6.67, suggesting 517.59% upside. Our AI forecast model points to short-term weakness (-12.96% over two weeks), a medium-term fall (-98.15% over three months), and a longer-term loss (-79.63% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Dermata Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -12.96%, with price expected at $0.94 by August 25, 2026, within a range of $0.89 to $0.99 3-Month Outlook: Projected fall of -98.15%, reaching $0.02 by November 09, 2026, with a range of $0.00 to $1.21. 1-Year Outlook: Projected loss of -79.63%, with price at $0.22 by August 11, 2027, within a range of $0.00 to $1.47.